Drugs / Nelarabine
last change 11 days ago re-read 9 days ago

Nelarabine

also known as 506U78 · 506U · Arranon · Atriance · Attriance · GW-506U78 · Nelarabina · Nelzarabine · +3 more

Small molecule

Developed for
leukemia · T-cell acute lymphoblastic leukemia · T-lymphoblastic lymphoma · acute lymphoblastic leukemia · adult T-cell leukemia/lymphoma · angioimmunoblastic T-cell lymphoma · lymphoma · mycosis fungoides and variants
+17 more · T-cell childhood acute lymphocytic leukemia · acute leukemia of ambiguous lineage · anaplastic large cell lymphoma · chronic lymphocytic leukemia/small lymphocytic lymphoma · lymphoid leukemia · MALT lymphoma · myelodysplastic syndrome · myeloproliferative neoplasm · nodal marginal zone B-cell lymphoma · plasma cell neoplasm · primary cutaneous T-cell non-Hodgkin lymphoma · small intestine lymphoma · splenic marginal zone lymphoma · T lymphoblastic leukemia/lymphoma · T-cell adult acute lymphocytic leukemia · T-cell leukemia · Waldenstrom macroglobulinemia
Investigated by
National Cancer Institute (NCI) · GlaxoSmithKline · Goethe University · M.D. Anderson Cancer Center · SWOG Cancer Research Network · Alliance for Clinical Trials in Oncology
+13 more · Assistance Publique - Hôpitaux de Paris · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Children's Cancer Group · National Institutes of Health (NIH) · Novartis · Novartis Pharmaceuticals · Spectrum Pharmaceuticals, Inc · St. Jude Children's Research Hospital · The Leukemia and Lymphoma Society · Therapeutic Advances in Childhood Leukemia Consortium · University College, London · University of Washington · Washington University School of Medicine

Regulatory milestones approvals, filings & regulatory actions · 3 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansion US (FDA) ARRANON — 2019-07-31 fda.gov ↗
Approved EU (EMA) Atriance — 2007-08-22 europa.eu ↗
Approved US (FDA) ARRANON — 2005-10-28 fda.gov ↗

Trials 21

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT01094860 Jun 2010 → Aug 2018 leukemia M.D. Anderson Cancer Center Completed No outcome recorded
Phase 1 NCT00004239 Dec 1999 → Jan 2002 leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, plasma cell neoplasm Alliance for Clinical Trials in Oncology Terminated No outcome recorded Stop: Enrollment
Phase 1/21 trial
Phase 1/2 NCT00981799 Jun 2010 → Nov 2015 T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma Therapeutic Advances in Childhood Leukemia Consortium Terminated No outcome recorded Stop: Enrollment
Phase 212 trials
Phase 2 NCT02763384 Dec 2016 → Feb 2022 T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma Washington University School of Medicine Terminated No outcome recorded Stop: Enrollment
Phase 2 NCT02518750 Nov 2016 → Mar 2018 T-cell leukemia, acute lymphoblastic leukemia St. Jude Children's Research Hospital Terminated No outcome recorded Stop: Enrollment
Phase 2 NCT02619630 Dec 2015 → Dec 2020 T-cell adult acute lymphocytic leukemia Assistance Publique - Hôpitaux de Paris Unknown No outcome recorded
Phase 2 NCT00501826 Jul 2007 → Oct 2028 expected T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma M.D. Anderson Cancer Center Recruiting No outcome recorded
Phase 2 NCT00684619 Jun 2003 → Dec 2008 T lymphoblastic leukemia/lymphoma Goethe University Completed No outcome recorded
Phase 2 NCT00006020 Jul 2000 → Jun 2004 leukemia SWOG Cancer Research Network Completed No outcome recorded
Phase 2 NCT00005080 May 2000 → Jan 2006 adult T-cell leukemia/lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, mycosis fungoides and variants +1 National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00005982 Apr 2000 → Jul 2004 mycosis fungoides and variants, primary cutaneous T-cell non-Hodgkin lymphoma National Cancer Institute (NCI) Terminated No outcome recorded
Phase 2 NCT00005950 Apr 2000 → Oct 2004 MALT lymphoma, Waldenstrom macroglobulinemia, adult T-cell leukemia/lymphoma, angioimmunoblastic T-cell lymphoma +3 National Cancer Institute (NCI) Terminated No outcome recorded
Phase 2 NCT00003635 Jan 1999 → Mar 2004 lymphoid leukemia GlaxoSmithKline Completed No outcome recorded
Phase 32 trials
Phase 3 NCT06434467 May 2024 → Dec 2025 T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Unknown No outcome recorded
Phase 3 NCT02881086 Aug 2016 → Dec 2024 acute lymphoblastic leukemia, lymphoblastic lymphoma Goethe University Completed No outcome recorded
Phase not applicable3 trials
— NCT02551718 Sep 2015 → Jun 2020 acute leukemia of ambiguous lineage, acute lymphoblastic leukemia University of Washington Completed No outcome recorded
— NCT00016302 Apr 2001 → Jul 2007 T-cell childhood acute lymphocytic leukemia National Cancer Institute (NCI) Completed No outcome recorded
— NCT00003837 Sep 1999 → Nov 2007 leukemia, lymphoma National Cancer Institute (NCI) Completed No outcome recorded
Phase not stated1 trial · 1 missed
— NCT01085617 Dec 2010 → Feb 2025 leukemia, mouth disorder, mucositis University College, London Completed Missed primary
Comparator or background therapy10 trials
Phase 1 NCT03328104 Background Jul 2018 → Jun 2023 T-lymphoblastic lymphoma Emory University Completed No outcome recorded
Phase 1 NCT00406757 Comparator Aug 2006 → Jul 2009 T lymphoblastic leukemia/lymphoma GlaxoSmithKline Completed No outcome recorded
Phase 1/2 NCT07294677 Background Mar 2026 → Mar 2032 expected leukemia, lymphoma University of Chicago Recruiting No outcome recorded
Phase 1/2 NCT03808610 Background Apr 2019 → May 2026 B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia M.D. Anderson Cancer Center Terminated No outcome recorded
Phase 2 NCT06390319 Background Dec 2024 → Dec 2027 expected T-cell acute lymphoblastic leukemia, T-cell non-Hodgkin lymphoma, mixed phenotype acute leukemia St. Jude Children's Research Hospital Recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2021-11-18 Zydus Lifesciences Limited Regulatory Zydus Cadila gets 180-day exclusivity for Nelarabine injection, announces final approval from USFDA zyduslife.com ↗
Zydus Cadila has received final approval from the USFDA to market Nelarabine Injection 250MG/50ML in the United States (US RLD: Arranon®).

All press releases naming this drug 1 release

DateIssuerRelease

Evidence & citations 14 cited values

Every value below carries the sentence it was read from. 33 sources stand behind the page.

FieldValueCited text
Known as nelarabine “Mitoxantrone Nelarabine Nilotinib” NCT02551718 ↗
29

NCT00006020 ↗

NCT00016302 ↗

NCT02881086 ↗

NCT00003635 ↗

NCT03020030 ↗

NCT03117751 ↗

NCT02619630 ↗

NCT07072585 ↗

NCT06390319 ↗

NCT00005982 ↗

Show 19 more sources

Known as 506U ChEMBL registry synonym — accepted as the source's own label CHEMBL1201112 ↗
Known as 506U78 “Nelarabine (506U78) is a soluble pro-drug of 9-beta-D-arabinofuranosylguanine (ara-G), a deoxyguanosine derivative.” PMID 17344466 ↗ Mar 2007
2

“Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or Lymphoma” NCT00406757 ↗

NCT00004239 ↗

Known as Arranon ChEMBL registry synonym — accepted as the source's own label CHEMBL1201112 ↗
Known as Atriance ChEMBL registry synonym — accepted as the source's own label CHEMBL1201112 ↗
Known as Attriance ChEMBL registry synonym — accepted as the source's own label CHEMBL1201112 ↗
Known as GW-506U78 ChEMBL registry synonym — accepted as the source's own label CHEMBL1201112 ↗
Known as Nelarabina ChEMBL registry synonym — accepted as the source's own label CHEMBL1201112 ↗
Known as Nelzarabine ChEMBL registry synonym — accepted as the source's own label CHEMBL1201112 ↗
Known as NSC #686673 “Compound 506U78 (NSC #686673)” NCT00004239 ↗
Known as NSC-755985 ChEMBL registry synonym — accepted as the source's own label CHEMBL1201112 ↗
Known as NSC-759876 ChEMBL registry synonym — accepted as the source's own label CHEMBL1201112 ↗
Modality Small molecule “Nelarabine (506U78) is a soluble pro-drug of 9-beta-D-arabinofuranosylguanine (ara-G), a deoxyguanosine derivative.” PMID 17344466 ↗ Mar 2007
Route Intravenous “Given IV” NCT00002970 ↗